Calidi Biotherapeutics, Inc.

Equities

CLDI

US3207031010

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
0.16 ^USD	-17.95%		-74.98%	-89.40%

Apr. 16	Calidi Biotherapeutics Prices $6.1 Million Offering	MT
Mar. 21	H.C. Wainwright Lowers Price Target on Calidi Biotherapeutics to $2 From $11, Maintains Buy Rating	MT

First Light Acquisition Group, Inc. Announces Executive Changes

September 16, 2022 at 05:18 pm EDT

Effective September 15, 2022, First Light Acquisition Group, Inc. appointed Thomas A. Vecchiolla as co-Chief Executive Officer to serve in such role with William J. Weber, who will also serve as co-Chief Executive Officer.

Latest news about Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics Prices $6.1 Million Offering	Apr. 16	MT
H.C. Wainwright Lowers Price Target on Calidi Biotherapeutics to $2 From $11, Maintains Buy Rating	Mar. 21	MT
Calidi Biotherapeutics, Inc. announced that it has received $3.5 million in funding	Mar. 20	CI
Calidi Biotherapeutics, Inc. announced that it expects to receive $3.5 million in funding	Mar. 07	CI
Sector Update: Health Care Stocks Firmer Late Afternoon	Feb. 07	MT
Calidi Biotherapeutics to Sell Common Stock	Feb. 07	MT
Calidi Biotherapeutics, Inc. announced that it has received $1 million in funding	Jan. 25	CI
Calidi Biotherapeutics, Inc. Announces Scientific and Medical Advisory Board Appointments	Jan. 08	CI
Calidi Biotherapeutics, Inc.(NYSEAM:CLDI) added to S&P TMI Index	Dec. 18	CI
Calidi Biotherapeutics Announces Directorate Changes	Dec. 12	CI
Calidi Biotherapeutics, Inc. announced that it expects to receive $25 million in funding from Yorkville Advisors Global LP	Dec. 09	CI
Calidi Biotherapeutics, Inc. Announces the Resignation of Alfonso Zulueta as A Director, Including His Position on Audit Committee of the Board	Dec. 05	CI
HC Wainwright Starts Calidi Biotherapeutics With Buy Rating, $11 Price Target	Nov. 22	MT
Calidi Biotherapeutics Gets US Patent for Cancer Treatment Technology Platform	Nov. 20	MT
Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting	Nov. 03	CI
Calidi Biotherapeutics, Inc. Announces Key Leadership Promotions and New Board Appointment	Nov. 01	CI
Calidi Biotherapeutics, Inc. announced a financing transaction	Oct. 31	CI
Calidi Biotherapeutics Names Andrew Jackson as Chief Financial Officer	23-10-30	MT
Calidi Biotherapeutics, Inc. Enters into an Employment Agreement with Andrew Jackson to Serve as Chief Financial Officer	23-10-30	CI
Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Interim Chief Financial Officer	23-10-27	CI
Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Chief Accounting Officer	23-10-27	CI
Calidi Biotherapeutics, Inc. Appoints Alan R. Stewart as the Class I Director	23-10-24	CI
Calidi Biotherapeutics, Inc. Announces the Resignation of Dr. Heehyoung Lee, Including All Her Positions on the Committees of the Board	23-10-16	CI
Baird Starts Calidi Biotherapeutics With Outperform Rating, Price Target is $9	23-10-09	MT
Calidi Biotherapeutics Announces Primary, Secondary Offering of Shares, Warrants	23-10-06	MT

Chart Calidi Biotherapeutics, Inc.

Duration

Period

More charts

Company Profile

Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its clinical-stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses. Its preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach shall potentially treat, or even prevent, metastatic disease. Its product candidates include CLD-101 for Recurrent HGG; CLD-201 for Advanced Solid Tumors, and CLD-400 (RTNova) for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline product candidates, the Company's is also engaged in discovery research of CLD-301 (AAA) for multiple Indications.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.16 USD

Average target price

3.25 USD

Spread / Average Target

+1,931.25%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CALIDI BIOTHERAPEUTICS, INC.	-89.40%	5.69M
VERTEX PHARMACEUTICALS INCORPORATED	-3.30%	102B
REGENERON PHARMACEUTICALS, INC.	+1.79%	96.07B
ARGENX SE	-0.44%	21.66B
BIONTECH SE	-18.35%	20.77B
GENMAB A/S	-7.45%	18.53B
WUXI APPTEC CO., LTD.	-40.31%	16.91B
BEIGENE, LTD.	-26.84%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.33B
SAREPTA THERAPEUTICS, INC.	+20.86%	10.94B

Bio Therapeutic Drugs